Navigation Links
Genzyme and Isis Complete Licensing of Mipomersen
Date:6/24/2008

Conference call to be held today at 10 a.m. EDT

CAMBRIDGE, Mass., and CARLSBAD, Calif., June 24 /PRNewswire-FirstCall/ -- Genzyme Corp. (Nasdaq: GENZ) and Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) today announced the finalization of the license and collaboration agreement for mipomersen. The collaboration provides Genzyme with exclusive worldwide rights to mipomersen, a novel lipid-lowering drug discovered and developed by Isis that is in phase 3 clinical development. During the second half of this year, enrollment is expected to be completed in a pivotal study of mipomersen in homozygous familial hypercholesterolemia, and a new trial in apheresis-eligible patients is expected to begin.

As part of the agreement, Isis will receive a $175 million license fee for mipomersen. In February, Isis received a $150 million payment from Genzyme to purchase 5 million shares of Isis common stock at $30 per share.

The companies have updated the deal terms so that Isis will contribute up to $50 million in additional development funding for mipomersen, bringing Isis' development funding commitment up to $125 million. Thereafter Isis and Genzyme will share development costs equally. The initial Isis development funding commitment and the shared funding will end when the program is profitable. In exchange for this additional contribution, Isis has the opportunity to receive $75 million in milestone payments early.

"Mipomersen is an innovative treatment that has the potential to change the standard of care for severely ill patients whose needs cannot be addressed by current cholesterol-lowering therapies," said Henri A. Termeer, Genzyme's chairman and chief executive officer. "This treatment is an important addition to
'/>"/>

SOURCE Genzyme Corporation; Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Preliminary Analyses from Phase 2 Genzyme Study Highlight Efficacy and Safety of Clofarabine in Older Adult AML Patients
2. Genzyme Genetics Announces Launch of Carrier Testing and Prenatal Diagnosis for Spinal Muscular Atrophy
3. Genzyme Announces Presentation of New Positive Data on Carticel(R)
4. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
5. Genzyme Completes Enrollment in Pivotal, Phase 2 Clinical Trial of Clofarabine in Adult AML
6. Genzyme and Bayer Schering Pharma AG, Germany Announce Start of Phase 3 Program with Alemtuzumab for Treatment of Multiple Sclerosis
7. Genzyme Announces Second Pivotal Mozobil Trial Meets Primary Endpoint
8. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
9. Metabolex Completes Patient Enrollment in Phase 2 Trial of MBX-8025 for Treatment of Dyslipidemia
10. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
11. Pharmaxis Long-Term Safety Study of Bronchitol Completes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... , Sept 23, 2014  Vesselon, Inc. today ... Board of Directors, effective September 15, 2014. Dr. Raths, ... as its placement agent to market a private preferred ... and early stroke treatment. "Jurgen,s deep experience ... be a great asset to Vesselon as we develop ...
(Date:9/23/2014)... DALLAS , September 23, 2014 ... "Ablation Technologies Market by Product (Radiofrequency, Ultrasound, Irreversible ... Cardiovascular, Cancer, Ophthalmology, Orthopedics) - Global Forecasts to ... Market over the forecast period of 2014 to ... Billion by 2019, at CAGR of 9.6% from ...
(Date:9/23/2014)... , Sept. 23, 2014 A case report ... a SynCardia temporary Total Artificial Heart into a patient ... ventricles were reversed, along with other abnormalities. ... modifying the SynCardia Total Artificial Heart to treat a ... report and video in the Journal of Visualized Experiments ...
Breaking Medicine Technology:Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 2Vesselon Announces Jurgen Raths, MD to Serve on Board of Directors 3Ablation Technologies Market Worth $3.81 Billion by 2019 2Ablation Technologies Market Worth $3.81 Billion by 2019 3Ablation Technologies Market Worth $3.81 Billion by 2019 41st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 21st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 31st Use of the SynCardia Total Artificial Heart in a 17-Year-Old Congenital Heart Disease Patient at Pediatric Hospital 4
... Korea , May 10 CrystalGenomics, Inc., a novel ... Ascending Dose) study for its novel antibiotic candidate, CG400549, has been ... , , ... targeting ENR (Enoyl-acyl carrier protein reductase, which is a critical enzyme ...
... May 10 Par Pharmaceutical Companies, Inc. (NYSE: ... Generics Limited and Glenmark Generics Inc., USA , has ... that resolves patent litigation related to Glenmark,s challenge to Merck,s ... involving a challenge by Glenmark which sought to launch a ...
Cached Medicine Technology:CrystalGenomics Announces Successful Completion of a Phase I SAD Clinical Trial for CG400549, its Novel Antibiotic Candidate 2Par's Development and Marketing Partner, Glenmark, Enters Into A Settlement Agreement With Merck To Settle Patent Litigation Over Generic ZETIA(R) 2
(Date:9/23/2014)... HealthDay Reporter TUESDAY, Sept. 23, 2014 (HealthDay ... breast milk is more likely than a blood transfusion to ... a new study finds. The researchers evaluated more than ... weighed 3.3 pounds or less and many who were born ... whether breast milk or transfusions carried the bigger risk. Infants ...
(Date:9/23/2014)... TUESDAY, Sept. 23, 2014 (HealthDay News) -- A test used ... geographic regions where certain lung infections are more common, a ... lung cancer is through the use of what,s known as ... imaging called FDG-PET is used, according to the study authors. ... do parts of the lungs that don,t have ...
(Date:9/23/2014)... with its advances promises of individualized genetic information ... Genetic tests are already guiding treatments of ... virus (HPC), and emerging research is showing genetic ... individual,s susceptibility to addiction to a substance, and ... appear to be many benefits inherent in the ...
(Date:9/23/2014)... Washington, DC (PRWEB) September 23, 2014 ... affordable care? The National Quality Forum (NQF) ... sheet ( http://www.qualityforum.org/WorkArea/linkit.aspx?LinkIdentifier=id&ItemID=77687 ), and an infographic ( ... the rising cost of healthcare, how patients define ... for consumers to get the best possible healthcare ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 What: ... Manhattan’s Upper West Side that embodies the inclusion ... Eden: Christians, Scripture and the Ecological Crisis, a ... B. Rhodes Professor Emerita of Old Testament at ... for ancient wisdom that lends insight into current ...
Breaking Medicine News(10 mins):Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Lung Infections May Hamper Ability to Detect Lung Cancer 2Health News:NYU-Mount Sinai Beth Israel study explores drug users' opinions on genetic testing 2Health News:Finding Affordable Care: Asking the Right Question is Key 2Health News:Inhabiting Eden: Christians, Scripture, and the Ecological Crisis – Public Lecture to Discuss Faith-Based Environmentalism 2
... revealed that women do not put on weight as a ... center said that the belief weight is gained as a ... such beliefs// are not based on facts. ... over the past few years that examined the effects of ...
... predisposed where smoking is concerned, according to a new research. ... habit. A gene which is called CYP2A6 serves to regulate ... for smoking addiction. ,People carry different forms ... particular parts of the world, and the Asiatic people show ...
... in the functioning of the heart with the progress of age ... according to a study which the Journal of the American College ... goes to show that primary aging can // be delayed by ... ,This fact has already been proved in the ...
... A DNA study conducted at the burial pits of ancient ... large-scale devastation to the city. The Golden Age of Athens ... this // epidemic, which is said to have wiped out ... epidemic was in Ethiopia, between 430-426 BC, which later spread ...
... dish ‘Haggis’ had an increased fat diet which the officials ... are now facing a high risk of getting obese and ... Haggis not more than once in a week. ... liver and heart of sheep which is mixed with oatmeal ...
... herbs along with conventional medical treatment for severe acute respiratory ... life// of such victims, according to latest reports. It may ... margin. ,The researchers of the present study ... of 654 SARS patients, treated with both allopathic and Chinese ...
Cached Medicine News: